Drug or treatment

Doxorubicin clinical trials

• 43Clinical trials
• 2New in 30 days
• 15Countries

Newest trials

All recruiting trials (43)

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

• Chemotherapy sensitivity-guided Culmerciclib combo for HR+/HER2- breast cancer before surgery

  This trial tests whether adding Culmerciclib to chemotherapy before surgery can help people with HR+/HER2- breast cancer who don’t respond to initial TAC treatment.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07900516

• Orelabrutinib plus Pola-R-CHP as first-line treatment for intermediate- to high-risk DLBCL

  This trial tests whether adding orelabrutinib to the Pola-R-CHP regimen can improve outcomes for adults with intermediate- to high-risk newly diagnosed DLBCL.

  Recruiting at 2 sites The First Affiliated Hospital of Xiamen University · Xiamen, Fujian and 1 other locations · NCT07778212

• Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer

  This study tests a treatment combination of Pyrotinib, Trastuzumab and chemo given before surgery to see if it can improve responses in HER2-positive breast cancer patients who have not yet been treated.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT07635342

• Polatuzumab vedotin with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in untreated DLBCL (MCD/BN2/N1)

  This study tests a targeted combination therapy to see if it can treat previously untreated DLBCL with specific molecular subtypes.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07608978

• Sacituzumab govitecan with bevacizumab vs standard chemotherapy for recurrent platinum-sensitive ovarian cancer after PARP inhibitor maintenance

  This phase II study tests whether sacituzumab govitecan plus bevacizumab can help people with recurrent platinum-sensitive ovarian cancer, after PARP inhibitor maintenance, more than the usual carboplatin, PLD, and bevacizumab treatment.

  Recruiting at 23 sites Phase 2 National Cancer Institute (NCI) · Fayetteville, Arkansas and 22 other locations · NCT07504588

• Bexmarilimab with doxorubicin for metastatic soft-tissue sarcoma

  This study tests whether adding bexmarilimab to doxorubicin is safe and helps people with metastatic soft-tissue sarcoma.

  Recruiting at 5 sites Phase 1/2 MedSIR · Badalona and 10 other locations · NCT07460986

• Compare SGLT-2 inhibitors vs DPP-4 inhibitors to prevent heart damage from doxorubicin in women with breast cancer

  This study tests whether a diabetes drug class (SGLT-2 inhibitors) or another (DPP-4 inhibitors) can help protect the heart of Egyptian women with breast cancer who are receiving doxorubicin chemotherapy.

  Recruiting Phase 4 Tanta University · Tanta, Elgharbeya · NCT07436663

• Using corticosteroids to reduce hand–foot skin reactions from liposomal doxorubicin

  This study will test whether giving corticosteroids around doses of liposomal doxorubicin can reduce painful hand–foot skin reactions in people with breast cancer receiving AC chemotherapy.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT07362914

• Envafolimab with doxorubicin and ifosfamide for advanced soft tissue sarcoma

  This trial will test whether adding envafolimab to doxorubicin and ifosfamide helps people with advanced soft tissue sarcoma respond better.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hanzhong, Zhejiang · NCT07243626

• Weekly low-dose doxorubicin for older adults with advanced leiomyosarcoma

  This trial will test whether giving doxorubicin at a lower dose once a week helps people aged 65–100 with advanced or metastatic leiomyosarcoma keep their cancer from getting worse.

  Recruiting Phase 2 University of Colorado, Denver · Aurora, Colorado · NCT07125183

• Epcoritamab plus dose‑adjusted EPOCH‑R for aggressive B‑cell lymphoma

  This trial tests whether adding epcoritamab to dose‑adjusted EPOCH‑R chemotherapy can safely improve outcomes for adults with untreated aggressive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07097363

• Phase II decentralized adjuvant doxorubicin plus trabectedin for uterine leiomyosarcoma

  This trial will try whether six cycles of doxorubicin plus trabectedin after surgery can prolong the time patients with stage 1b or 2 uterine leiomyosarcoma remain cancer-free.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07076186

• Single-protein encapsulated doxorubicin (SPEDOX-6) for advanced solid tumors

  We will try SPEDOX-6, a protein-encapsulated form of doxorubicin, to find a safe dose and see if it helps adults with advanced, treatment-resistant solid tumors (including certain sarcomas, triple-negative breast cancer, non-small cell lung cancer, cervical, ovarian, and KRAS‑mutant pancreatic cancers) who have not rec

  Recruiting Phase 1/2 University of California, Irvine · Orange, California · NCT07064018

• Neoadjuvant atezolizumab and doxorubicin with preoperative radiation and adjuvant atezolizumab for high‑risk resectable limb and trunk soft tissue sarcoma

  This will test whether adding the immunotherapy atezolizumab to doxorubicin chemotherapy before surgery, with radiation before surgery and more atezolizumab after surgery, can delay relapse in adults with high‑risk, resectable soft tissue sarcoma of the arms, legs, or trunk.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07049848

• Maintenance pegylated liposomal doxorubicin versus observation for advanced soft tissue sarcoma after anthracycline control (MELODY)

  This trial tests whether giving maintenance pegylated liposomal doxorubicin (PLD) every 4 weeks helps people with advanced soft tissue sarcoma whose disease was controlled after first-line anthracycline chemotherapy, compared with active surveillance.

  Recruiting at 7 sites Phase 2 National Health Research Institutes, Taiwan · Kaohsiung City and 6 other locations · NCT06981637

• Combining immune therapy with chemotherapy for advanced soft tissue sarcoma

  This study is testing if combining a new immune therapy with standard chemotherapy can help people with advanced soft tissue sarcoma who can’t have surgery or radiation feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06849986

• Gudinutuximab Beta Added to Standard Chemo for GD2-Positive Ewing Sarcoma (Early-Phase Trial)

  This early-phase study tests whether adding dinutuximab beta to standard VDC/IE chemotherapy is feasible and safe for patients with GD2-positive high-risk Ewing sarcoma.

  Recruiting at 3 sites Phase 1 German Society for Pediatric Oncology and Hematology GPOH gGmbH · Göttingen, Lower Saxony and 4 other locations · NCT06839703

• Combining brentuximab vedotin with standard chemotherapy for Hodgkin lymphoma in adults

  This study is testing if adding a new drug called brentuximab vedotin to standard chemotherapy can help adults with untreated Hodgkin lymphoma feel better and improve their treatment results.

  Recruiting at 5 sites Phase 4 Takeda · Vijayawada, Andhra Pradesh and 10 other locations · NCT06831370

• Evaluating RC220 with Doxorubicin for Advanced Solid Tumours

  This study is testing a new treatment called RC220, both alone and with doxorubicin, to see if it is safe and works for adults with advanced solid tumors.

  Recruiting at 5 sites Phase 1 Racura Oncology Ltd · Gosford, New South Wales and 8 other locations · NCT06815575

• Combining pegylated liposomal doxorubicin and adebrelimab with or without mirabegron for relapsed ovarian cancer

  This study is testing a new treatment combination for adults with relapsed ovarian cancer to see if adding mirabegron to pegylated liposomal doxorubicin and adebrelimab makes it work better.

  Recruiting Phase 2/3 Obstetrics & Gynecology Hospital of Fudan University · Shanghai, Shanghai Municipality · NCT06791460

• Combining Anlotinib with Doxorubicin and Radiotherapy for Soft Tissue Sarcoma Treatment

  This study is testing if combining a cancer drug called anlotinib with chemotherapy and radiation can help people with high-grade soft tissue sarcoma have better treatment results before surgery.

  Recruiting at 2 sites Phase 4 Guangdong Provincial People's Hospital · Guangzhou, Guangdong and 1 other locations · NCT06506838

• Tamoxifen plus pegylated liposomal doxorubicin for advanced triple-negative breast cancer

  This trial tests whether combining tamoxifen with pegylated liposomal doxorubicin can shrink or control metastatic or inoperable locally advanced triple-negative breast cancer in patients with low ER expression and a confirmed TP53 genomic alteration who have had prior therapies.

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT06434064

• Dapagliflozin to prevent heart damage from doxorubicin in breast cancer

  This trial will test if taking dapagliflozin can prevent heart damage in adults with early-stage breast cancer who are receiving doxorubicin chemotherapy.

  Recruiting Phase 2 Tanta University · Alexandria, Bab Sharqi · NCT06427226

• Combining immunotherapy with chemotherapy for aggressive sarcomas

  This study is testing if combining immunotherapy with chemotherapy can help people with aggressive sarcomas live longer and feel better compared to just using chemotherapy alone.

  Recruiting at 247 sites Phase 3 National Cancer Institute (NCI) · Phoenix, Arizona and 268 other locations · NCT06422806

• MASCT-I plus doxorubicin and ifosfamide as first-line treatment for advanced soft tissue sarcoma

  This trial will test whether adding MASCT-I to standard chemotherapy (doxorubicin and ifosfamide) helps adults with advanced soft tissue sarcoma respond better or live longer.

  Recruiting Phase 2 HRYZ Biotech Co. · Guangzhou · NCT06277154

• Treatment for Richter Syndrome using Glofitamab with Rituximab or Obinutuzumab plus CHOP

  This study is testing if a new treatment combining Glofitamab with Rituximab or Obinutuzumab and CHOP chemotherapy can help people with untreated Richter Syndrome feel better.

  Recruiting at 6 sites Phase 2 French Innovative Leukemia Organisation · Amiens and 22 other locations · NCT06186648

• Combining an immunotherapy drug with standard chemotherapy for advanced breast cancer

  This study is testing if adding an immunotherapy drug called durvalumab to standard chemotherapy can help people with advanced hormone receptor-positive, HER2-negative breast cancer live longer and feel better.

  Recruiting at 552 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 564 other locations · NCT06058377

• Observing the effects of liposomal doxorubicin in breast cancer treatment

  This study is testing how well liposomal doxorubicin works and how safe it is for women aged 18-75 who are getting treatment after surgery for breast cancer.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT05731258

• Testing a new combination of chemotherapy drugs for advanced sarcoma

  This study is testing a new combination of chemotherapy drugs to see if it can help people with advanced sarcoma feel better and manage their disease.

  Recruiting at 15 sites Phase 1 National Cancer Institute (NCI) · Los Angeles, California and 15 other locations · NCT05711615

• Combining NEROFE and Doxorubicin for KRAS-mutated Solid Tumors

  This study is testing if a new treatment called NEROFE, when combined with the cancer drug doxorubicin, can help people with advanced solid tumors that have a KRAS mutation and haven't responded to other treatments.

  Recruiting Phase 1 Georgetown University · Washington D.C., District of Columbia · NCT05661201

• Combination therapy for recurrent ovarian cancer using doxorubicin and Ashwagandha

  This study is testing if a combination of a cancer drug and Ashwagandha can help women with recurrent ovarian cancer feel better and respond to treatment.

  Recruiting Phase 1/2 University of Louisville · Louisville, Kentucky · NCT05610735

• Combining Doxorubicin Liposome and Irinotecan for Pediatric Rhabdomyosarcoma Treatment

  This study is testing a new combination of two chemotherapy drugs to see if it can help children with a tough-to-treat type of cancer called rhabdomyosarcoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou · NCT05457829

• Microneedle patches delivering doxorubicin for skin cancer treatment

  This study is testing a new way to treat skin cancer by using tiny microneedle patches to deliver a cancer-fighting drug directly to the tumor, focusing on both healthy and immunocompromised patients.

  Recruiting Phase 1/2 University of Pittsburgh · Pittsburgh, Pennsylvania · NCT05377905

• Combining disulfiram, copper gluconate, and liposomal doxorubicin for treating relapsed sarcomas

  This study is testing a new treatment that combines disulfiram, copper gluconate, and liposomal doxorubicin to see if it can help people with relapsed sarcomas feel better and live longer.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT05210374

• Comparing two treatment regimens for HER-2 positive breast cancer

  This study is testing two different treatment plans for people with HER-2 positive breast cancer to see which one works better before surgery.

  Recruiting Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guandong, Guangdong · NCT05159193

• Combining two chemotherapy drugs for advanced angiosarcoma treatment

  This study is testing a new combination of two chemotherapy drugs to see if it can help people with advanced angiosarcoma who haven't had success with other treatments.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT04859465

• Combination of PIPAC and systemic chemotherapy for advanced ovarian cancer

  This study is testing a new way to give chemotherapy for women with advanced ovarian cancer who haven't responded well to previous treatments, by combining a special spray method with regular chemotherapy to see how safe it is and what the best dose is.

  Recruiting at 6 sites Phase 1 Hospices Civils de Lyon · Lille and 5 other locations · NCT04811703

• Sequential chemotherapy for soft tissue sarcoma

  This study tests if giving two types of chemotherapy before surgery can help people with high-grade soft tissue sarcoma live longer and be cancer-free.

  Recruiting at 2 sites Phase 2 Oslo University Hospital · Bergen and 1 other locations · NCT04776525

• Treatment for Primary Mediastinal Large B-cell Lymphoma with Antibody Therapy and ImmunoChemotherapy

  This study is testing a new combination of antibody therapy and chemotherapy to see if it helps people with untreated primary mediastinal large B-cell lymphoma feel better and improve their quality of life.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT04745949

• Using sulforaphane to protect the heart during breast cancer treatment with doxorubicin

  This study is testing if a nutritional supplement called sulforaphane can help protect the hearts of breast cancer patients receiving doxorubicin chemotherapy.

  Recruiting Phase 1/2 Texas Tech University Health Sciences Center · Lubbock, Texas · NCT03934905

• Comparing two chemotherapy regimens for children with advanced kidney tumors

  This study is testing if a new combination of chemotherapy drugs can help children with advanced kidney tumors do better than the standard treatment.

  Recruiting Phase 3 Assistance Publique Hopitaux De Marseille · Marseille · NCT03669783

• Pembrolizumab plus pegylated liposomal doxorubicin for endocrine‑resistant ER+ HER2‑ metastatic breast cancer

  This trial will try pembrolizumab with pegylated liposomal doxorubicin in women with endocrine‑resistant, ER‑positive, HER2‑negative metastatic breast cancer who have had at least two prior hormonal therapies.

  Recruiting Phase 1/2 Shaare Zedek Medical Center · Jerusalem · NCT03591276

Quick answers

How many clinical trials of Doxorubicin are recruiting right now?

43, as of November 12, 2026. 2 of them were first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 15 countries. The most sites are in United States (16 trials), China (15 trials), France (3 trials), Puerto Rico (2 trials), Egypt (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 19, Phase 1: 6, Phase 1/2: 6, Phase 3: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →